High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: Results of the REDERT study

Nephrology Dialysis Transplantation

Volumn 30, Issue 4, 2015, Pages 682-689

  Panichi, Vincenzo ^a   Scatena, Alessia ^a   Rosati, Alberto ^b   Giusti, Riccardo ^b   Ferro, Giuseppe ^c   Malagnino, Erasmo ^b   Capitanini, Alessandro ^d   Piluso, Adriano ^d   Conti, Paolo ^e   Bernabini, Giada ^e   Migliori, Massimiliano ^a   Caiani, David ^c   Tetta, Ciro ^f   Casani, Aldo ^g   Betti, Giancarlo ^g   Pizzarelli, Francesco ^c  

^a Versilia Hospital   (Italy)

^b Lucca Hospital   (Italy)

^c Firenze OSMA   (Italy)

^d PISTOIA HOSPITAL   (Italy)

^e Grosseto Hospital   (Italy)

^f FRESENIUS MEDICAL CARE   (Germany)

^g Massa Carrara hospital   (Italy)

Author keywords

C reactive protein; chronic inflammation; ESA resistance; hepcidin; online haemodiafiltration

Indexed keywords

ANTIANEMIC AGENT; BETA 2 MICROGLOBULIN; BICARBONATE; C REACTIVE PROTEIN; FERRITIN; HEPCIDIN; IRON; POLYSULFONE; TRANSFERRIN; HEMODIALYSIS FLUID; HEMOGLOBIN;

AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; ERYTHROPOIESIS STIMULATING AGENT RESISTANCE INDEX; FEMALE; HEMODIAFILTRATION; HIGH VOLUME ONLINE HEMODIAFILTRATION; HUMAN; IRON INTAKE; MALE; MEDICAL PARAMETERS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UREMIA; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; DRUG RESISTANCE; ERYTHROPOIESIS; INFLAMMATION; METABOLISM; ONLINE SYSTEM; PROCEDURES; PROSPECTIVE STUDY;

AGED; ANEMIA; BICARBONATES; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DRUG RESISTANCE; ERYTHROPOIESIS; FEMALE; HEMATINICS; HEMODIAFILTRATION; HEMODIALYSIS SOLUTIONS; HEMOGLOBINS; HEPCIDINS; HUMANS; INFLAMMATION; IRON; MALE; ONLINE SYSTEMS; PROSPECTIVE STUDIES; UREMIA;

EID: 84926682540     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu345     Document Type: Article

References (45)

1. Stenvinkel P, Barany P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress. Nephrol Dial Transplant 2002; 17 (Suppl 5): 32-37
2. Locatelli F, Aljama P, Barany P et al. European best practice guidelines working group: revised European best practice guidelines for management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (Suppl 2): ii1-ii47
3. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S11-S17
4. Tsai A, Berns JS. Use of erythropoietic-stimulating agents in hemodialysis patients. In: Nissenson AR, Fine RN, (eds). Handbook of Dialysis Therapy. 4th edn. Philadelphia, PA: Saunders Elsevier, 2008: 771-785
5. Smrzova J, Balla J, Bárány P. Inflammation and resistance to erythropoiesis-stimulating agents-what do we know and what needs to be clarified? Nephrol Dial Transplant 2005; 20 (Suppl 8): viii2-viii7
6. Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest 2005; 35 (Suppl 3): 32-35
7. Panichi V, Rosati A, Bigazzi R et al. Anemia and resistance to erythropoiesis-stimulating agents as prognostic factors in hemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011; 26: 2641-2648
8. Papanikolaou G, Tzilianos M, Christakis JI et al. Hepcidin in iron overload disorders. Blood 2005; 105: 4103-4105
9. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093
10. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276
11. Ronco C, Cruz D. Hemodiafiltration history, technology, and clinical results. Adv Chronic Kidney Dis 2007; 14: 231-243
12. Ledebo I, Blankestijn PJ. Haemodiafiltration-optimal efficiency and safety. NDT Plus 2010; 3: 8-16
13. Carracedo J, Merino A, Nogueras S et al. On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocytederived dendritic cells: a prospective, crossover study. J Am Soc Nephrol 2006; 17: 2315-2321
14. Filiopoulos V, Hadjiyannakos D, Metaxaki P et al. Inflammation and oxidative stress in patients on hemodiafiltration. Am J Nephrol 2008; 28: 949-957
15. Panichi V, Rizza GM, Paoletti S et al. Chronic inflammation and mortality in hemodialysis: effect of different renal replacement therapies: results from the RISCAVID study. Nephrol Dial Transplant 2008; 23: 2337-2343
16. Grooteman MP, van den Dorpel MA, Bots ML et al. CONTRAST Investigators. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012; 23: 1087-1096
17. Ok E, Asci G, Toz H et al. Turkish Online Haemodiafiltration Study. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant. 2013; 28: 192-202
18. Maduell F, Moreso F, Pons M et al. ESHOL Study Group. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24: 487-497
19. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213
20. Zaritsky J, Young B, Gales B et al. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010; 5: 1010-1014
21. van der Weerd NC, Den Hoedt CH, Blankestijn PJ et al. CONTRAST Investigators. Resistance to erythropoiesis stimulating agents in patients treated with online hemodiafiltration and ultrapure low-flux hemodialysis: results from a randomized controlled trial (CONTRAST). PLoS One 2014; 9: e94434
22. Locatelli F, Altieri P, Andrulli S et al. Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial. Nephrol Dial Transplant 2012; 27: 3594-3600
23. Schiffl H. Prospective randomized cross-over long-term comparison of online haemodiafiltration and ultrapure high-flux haemodialysis. Eur J Med Res 2007; 12: 26-33
24. Vaslaki L, Major L, Berta K et al. On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif 2006; 24: 163-173
25. Bonforte G, Grillo P, Zerbi S et al. Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line prepared substitution fluid. Blood Purif 2002; 20: 357-363
26. Tripepi G, Malalmaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16: S83-S88
27. Zoccali C, Tripepi G, Malalmaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 2006; 17: S169-S173
28. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565-568
29. Kalantar-Zadeh K, Kleiner M, Dunne E et al. Total iron-binding capacityestimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 1998; 31: 263-272
30. Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001; 38: 1343-1350
31. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808
32. Wei M, Bargman JM, Oreopoulos DG. Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis. Int Urol Nephrol 2007; 39: 935-940
33. Bradbury BD, Critchlow CW,Weir MR et al. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant 2009; 24: 919-925
34. Del Vecchio L, Pozzoni P, Andrulli S et al. Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 2005; 15: 137-141
35. Shinzato T, Abe K, Furusu A et al. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. Med Sci Monit 2008; 14: CR431-7
36. Costa E, Lima M, Alves JM et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol 2008; 28: 268-275
37. Park CH, Valore EV, Waring AJ et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810
38. Krause A, Neitz S, Mägert HJ et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 147-150
39. van derWeerd NC, Grooteman MP, Bots ML et al. CONTRAST Investigators. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012; 7: e39783
40. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726-741
41. Ashby DR, Gale DP, BusbridgeMet al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75: 976-981
42. Weiss G, Theurl I, Eder S et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009; 39: 883-890
43. Stefánsson BV, Abramson M, Nilsson U et al. Hemodiafiltration improves plasma 25-hepcidin levels: a prospective, randomized, blinded, cross-over study comparing hemodialysis and hemodiafiltration. Nephron Extra 2012; 2: 55-65
44. Maduell F, del Pozo C, Garcia H et al. Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999; 14: 1202-1207
45. Tiranathanagul K, Praditpornsilpa K, Katavetin P et al. On-line hemodiafiltration in Southeast Asia: a three-year prospective study of a single center. Ther Apher Dial 2009; 13: 56-62